Why Aptevo's Stock Is Trading Higher Today

Aptevo Therapeutics (NASDAQ: APVO) shares are trading higher on Tuesday after the company announced the first complete remission in a patient was observed in the ongoing APVO436 Phase 1 clinical trial.

Aptevo Therapeutics is a biosciences company. The company is engaged in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline product includes Otlertuzumab, APVO414, Multiple ADAPTIR Candidates, ALG.APV-527, APVO436 and APVO210.

Aptevo Therapeutics shares were trading up 19.37% at $7.52 on Tuesday during the time of publication. The stock has a 52-week high of $11.73 and a 52-week low of $2.94.